Martin Daniel G. 4
4 · NovAccess Global Inc. · Filed Sep 9, 2020
Insider Transaction Report
Form 4
Martin Daniel G.
DirectorChief Executive Officer10% Owner
Transactions
- Other
Common Stock, no par value
2020-09-08+7,500,000→ 7,500,000 total(indirect: By Innovest Global, Inc.) - Other
Series B Preferred Stock, $0.01 par value
2020-09-08+25,000→ 25,000 total(indirect: By LLC)Exercise: $0.00From: 2020-09-08→ Common Stock, no par value (250,000,000 underlying) - Other
Series A Preferred Stock, $0.01 par value per share
2020-09-04−5,000→ 0 total(indirect: By LLC) - Other
Series B Preferred Stock, $0.01 par value per share
2020-09-04+25,000→ 25,000 total(indirect: By LLC)
Footnotes (3)
- [F1]On September 4, 2020, NovAccess Global Inc. (the "Company") redeemed 5,000 shares of Series A preferred stock held by TN3, LLC ("TN3") for 25,000 shares of the Company's Series B preferred stock. The holder of the Company's shares of Series A preferred is entitled to cast a number of votes equal to that number of common shares of the Company which is not less than 60% of the vote required to approve an action on all matters voted on the Company's shareholders. Each share of Series B preferred in convertible by the holder into 10,000 shares of the Company's common stock and entitles the holder to cast 40,000 votes on all matters voted on by the Company's shareholders.
- [F2]On September 8, 2020, the Company issued 7,500,000 shares of common stock to Innovest Global, Inc. ("Innovest") for all of the outstanding interests of StemVax, LLC. Mr. Martin is the chairman and a significant shareholder of Innovest. Mr. Martin disclaims beneficial ownership of the shares of the Company's common stock held by Innovest.
- [F3]None.